top of page
Insights That Move the GPCR Field Forward
Read the latest analyses, interviews, and discoveries shaping the GPCR ecosystem — from research breakthroughs to biotech strategy.
Blog: Blog2
Search


The Moment Biotech Founders Realize the Money Is Gone
👉 Most biotech founders do not realize they are in trouble when the money runs out. By then, the situation is already decided. 👉 The real issue begins earlier, at a point where the company is still operating, the science is progressing, and milestones are being met. On paper, things look fine. In reality, something more subtle starts to shift. 👉 Decision-making changes. Plans that once felt flexible start to feel constrained. Conversations move from options to assumption

Attila Foris
Feb 166 min read


The Hidden Cost of Unclear Biotech Positioning
👉 Most biotech founders experience that external conversations consume more energy than they should . Investor calls take too long before reaching substance. Partner discussions sound positive but rarely lead to concrete next steps. Business development conversations feel inconsistent, even when the company and the science have not changed. 👉 The natural reaction is to improve communication. Founders refine their pitch, rewrite slides, and rehearse explanations. Yet better

Attila Foris
Jan 286 min read


The One Reason Why Biotech Startups Fail More Often Than They Should
Biotech startups rarely fail all at once. They fail while everyone is still working hard. Experiments continue. Meetings happen. Progress is reported. Yet alignment fades and decisions lose clarity. This is not a motivation problem. It is structural. When complexity grows faster than strategy, biotech companies drift. Survival depends less on science and more on whether clarity scales with complexity.

Attila Foris
Jan 75 min read


FDA Approval Is a Strategy Obstacle, Not a Paperwork Problem
The Gaps They Already See 👉 As a biotech founder, it’s easy to mistake volume for readiness . A solid preclinical package, promising safety data, and a consistent in vivo proof-of-concept, it feels like you’re ready for that pre-IND meeting. And yet, many founders walk out of their first FDA conversation with a quiet sense of confusion . 👉 No dramatic rejection. No loud red flags.Just a series of subtle but firm questions pointing to what’s missing . While you’re focused on

Attila Foris
Dec 10, 20255 min read


How to Avoid the Most Common Gaps in Your Biotech Pitch
The Cost of Confusion Let’s be honest. Most biotech pitches don’t fail because the science is weak. They fail because the story is unclear. 👉 A confusing pitch doesn’t just slow down progress. It silently shuts down opportunity. You might still get the meeting. You might still get a few questions. But behind the polite nods, your audience is checking out. Here’s the uncomfortable truth: 👉 People make up their minds in the first few seconds. If your pitch doesn’t immediately

Attila Foris
Dec 3, 20255 min read
bottom of page


